Known targets — ChEMBL curated mechanism
KCNA5KCND3KCNH2KCNJ3KCNJ5SCN5A
The experimentally established mechanism targets of Vernakalant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 known ✓ | P22460 | 6/20 | 1.00 |
| ▸ | SCN5A known ✓ | Q14524 | 6/20 | 1.00 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 1.00 |
| ▸ | KCND2 | Q9NZV8 | 5/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vernakalant SCHEMBL1762185 | 1.00 | KCNA5 (1.00) | KCNA5SCN5AKCND2KCNH2SLC6A4 | |
| Vernakalant SCHEMBL439144 | 1.00 | KCNA5 (1.00) | KCNA5SCN5AKCND2KCNH2SLC6A4 | |
| Vernakalant SCHEMBL441544 | 1.00 | KCNA5 (1.00) | KCNA5SCN5AKCND2KCNH2SLC6A4 | |
| Vernakalant SCHEMBL6276115 | 1.00 | KCNA5 (1.00) | KCNA5SCN5AKCND2KCNH2SLC6A4 | |
| Vernakalant SCHEMBL4615829 | 1.00 | KCNA5 (1.00) | KCNA5SCN5AKCND2KCNH2SLC6A4 | |
| Vernakalant SCHEMBL3338844 | 1.00 | KCNA5 (1.00) | KCNA5SCN5AKCND2KCNH2SLC6A4 | |
| Vernakalant SCHEMBL439706 | 1.00 | KCNA5 (1.00) | KCNA5SCN5AKCND2KCNH2SLC6A4 | |
| Vernakalant SCHEMBL443797 | 1.00 | KCNA5 (1.00) | KCNA5SCN5AKCND2KCNH2SLC6A4 | |
| Vernakalant SCHEMBL442387 | 1.00 | KCNA5 (1.00) | KCNA5SCN5AKCND2KCNH2SLC6A4 | |
| Vernakalant SCHEMBL441030 | 1.00 | KCNA5 (1.00) | KCNA5SCN5AKCND2KCNH2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114436928-A | Crystalline form A of Vernakalant hydrochloride and preparation method thereof | 上海旭东海普药业有限公司 | 2022-05-06 | — | — | CN | claimed |
| CN-114105847-A | Refining method of Vernakalant hydrochloride | 上海旭东海普药业有限公司 | 2022-03-01 | — | — | CN | claimed |
| CN-114031535-A | Improved synthesis method of vernakalant hydrochloride | 上海旭东海普药业有限公司 | 2022-02-11 | — | — | CN | claimed |
| US-20070197632-A1 | Aminocyclohexyl ether compounds and uses thereof | CARDIOME PHARMA CORP (CA) | 2007-08-23 | — | — | US | claimed |
| EP-1560812-B1 | AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP (CA) | 2006-05-10 | — | — | EP | claimed |
| EP-2841109-B1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA AS (DK) | 2026-04-15 | — | — | EP | disclosed |
| US-12485088-B2 | Rapidly-orodispersible tablets having an interior cavity | Aprecia Pharmaceuticals LLC (US) | 2025-12-02 | — | — | US | disclosed |
| US-12324856-B2 | Oral drug dosage form comprising drug in the form of nanoparticles | Triastek, Inc. (CN) | 2025-06-10 | — | — | US | disclosed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| EP-4512394-A2 | DOSAGE FORMS AND USE THEREOF | Triastek, Inc. (CN) | 2025-02-26 | — | — | EP | disclosed |
| US-20240408023-A1 | DOSAGE FORMS OF CONTROLLED RELEASE AT SPECIFIC GASTROINTESTINAL SITES | Triastek, Inc. (CN) | 2024-12-12 | — | — | US | disclosed |
| EP-4171518-B1 | RAPIDLY-ORODISPERSIBLE TABLETS HAVING AN INTERIOR CAVITY | Aprecia Pharmaceuticals LLC (US) | 2024-12-11 | — | — | EP | disclosed |
| WO-2005097203-A2 | SERUM PROTEIN CONJUGATES OF ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2005-10-20 | — | — | WO | disclosed |
| WO-2005097087-A2 | MERGED ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2005-10-20 | — | — | WO | disclosed |
| WO-2005094897-A2 | PEGYLATED ION CHANNEL MODULATING COMPOUNDS | CARDIOME PHARMA CORP. (CA) | 2005-10-13 | — | — | WO | disclosed |
| US-20050119315-A1 | Ion channel modulating activity II | CARDIOME PHARMA CORP. (CA) | 2005-06-02 | — | — | US | disclosed |
| US-20050070552-A1 | Ion channel modulating activity I | CARDIOME PHARMA CORP. (CA) | 2005-03-31 | — | — | US | disclosed |
| WO-2005020975-A2 | TREATMENT OF LEARNING DISABILITIES AND MOTOR SKILLS DISORDER WITH NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| US-20050038256-A1 | Synthetic process for trans-aminocyclohexyl ether compounds | CARDIOME PHARMA CORP. (CA) | 2005-02-17 | — | — | US | disclosed |
| US-20050026993-A1 | Uses of ion channel modulating compounds | CORREVIO CANADA CORP. (CA) | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119315-A1 | Ion channel modulating activity II | KCNH1, KCNN3, KCNJ2 | KCNA5 34/4885SCN5A 64/4885KCNH2 11/4885 |
| US-20050070552-A1 | Ion channel modulating activity I | KCNN1, KCNN3, KCNH1 | KCNA5 45/4885SCN5A 71/4885KCNH2 13/4885 |
| US-12324856-B2 | Oral drug dosage form comprising drug in the form of nanoparticles | CYP2D6, CYP3A5, CYP3A7 | KCNA5 4057/4885SCN5A 1450/4885KCNH2 4857/4885 |
| US-20070197632-A1 | Aminocyclohexyl ether compounds and uses thereof | KCNH2, KCNC1, KCNH3 | KCNA5 16/4885SCN5A 24/4885KCNH2 1/4885 |
| US-20050038256-A1 | Synthetic process for trans-aminocyclohexyl ether compounds | AKR1C3, CBR1, CBR3 | KCNA5 3636/4885SCN5A 3138/4885KCNH2 1685/4885 |
| US-20050026993-A1 | Uses of ion channel modulating compounds | KCNN1, KCNN2, KCNN3 | KCNA5 48/4885SCN5A 49/4885KCNH2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.